While previous reviews have predominantly focused on its therapeutic and nutraceutical applications or cultivation methods in isolation, the present review stands out by holistically integrating multiple dimensions, from traditional and modern cultivation practices to substrate-based nutritional profiling, validated therapeutic claims, and sustainable valorization of spent mushroom substrate
News provided by Novo Nordisk Jul 01, 2026, 07:00 ET Starting today, eligible Medicare patients living with obesity can access Wegovy (semaglutide) injection and pill for a $50 monthly copay Wegovy offers adults living with obesity significant weight loss, along with diet and exercise, and is FDA-approved to lower the risk of major cardiovascular events including death, heart attack, or stroke in adults with obesity and heart disease a claim only Wegovy can make Since launching in January 2026, Wegovy pill has reached 3 million prescriptions * Medicare GLP-1 Bridge participation now expands patient access to authentic, FDA-approved Wegovy , including the Wegovy pill PLAINSBORO, N.J., July 1, 2026 /PRNewswire/ -- Starting today FDA-approved Wegovy (semaglutide) is available through the Medicare GLP-1 Bridge, a new access pathway for millions of older adults living with obesity
Endocrinology 149 , 47684777, (2008)
doi:10.1016/j.pnpbp.2017.03.021
